BofA Bullish on Johnson & Johnson as Pipeline Momentum Drives Target Hike

Bank of America’s decision to raise its price target for Johnson & Johnson (JNJ) on March 12, 2026, marks a significant vote of confidence in the healthcare giant’s post-spinoff trajectory. Since completing the separation of its consumer health business, Kenvue, JNJ has aggressively repositioned itself as a pure-play leader in high-growth Innovative Medicine and Medical Technology. This strategic narrowing of focus appears to be yielding tangible results, as evidenced by a flurry of regulatory successes and market performance that recently pushed the stock to a new 12-month high.

The core of BofA’s bullish thesis rests on JNJ’s 'Innovative Medicine' pipeline, which has seen exceptional productivity in early 2026. On March 5, the U.S. Food and Drug Administration (FDA) granted approval for a new multiple myeloma combination therapy as a second-line treatment, significantly expanding the addressable patient population for JNJ’s oncology portfolio. This was followed closely on March 7 by a fast-track approval for the Tecvayli-Darzalex combination, a potent treatment for blood cancer. These approvals are not merely incremental; they represent JNJ’s ability to defend its dominant position in the oncology market against intensifying competition from peers like AbbVie and Bayer.

“

This institutional profit-taking may reflect broader portfolio rebalancing rather than a lack of faith in JNJ’s fundamentals, especially as the company approaches its ambitious goal of $57 billion in pharmaceutical sales by the end of 2025.

Beyond pharmaceuticals, JNJ’s MedTech division is emerging as a critical growth engine. Industry analysts project the global minimally invasive surgical devices market to grow at a compound annual growth rate (CAGR) of approximately 7% through 2034. JNJ, through its DePuy Synthes and Ethicon subsidiaries, is uniquely positioned to capture this tailwind. The company’s recent investments in robotic-assisted surgery and digital integration within the operating room are designed to improve surgical outcomes while securing long-term service revenue, a shift that BofA analysts likely view as a stabilizer against the more volatile drug development cycles.